CLDN8 Plays A Crucial Role in Cell-cell Adhesion and Neurodegenerative Diseases

Target Name: CLDN8

NCBI ID: G9073

CLDN8

CLDN8 Plays A Crucial Role in Cell-cell Adhesion and Neurodegenerative Diseases

Claudin 8 (CLDN8) is a protein that is expressed in the endothelial cells of the body. It plays a critical role in cell-cell adhesion and has been implicated in various diseases, including heart disease, cancer, and neurodegenerative diseases.

The Importance of CLDN8 in Health

CLDN8 has been shown to be involved in several important biological processes in the body, including:

1. Cell-cell Adhesion: CLDN8 helps to maintain the integrity of cell-cell adhesion by regulating the interaction between adhesion molecules and the cytoskeleton. This is important for the proper functioning of tissues and organs and is implicated in various diseases, including cancer.
2. Signal Transduction: CLDN8 is involved in the regulation of intracellular signaling pathways, including the TGF-β pathway. This pathway is involved in the development and maintenance of tissues and organs and is a target for many drugs that are used to treat diseases, including cancer.
3. Neurodegenerative Diseases: CLDN8 has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. This is because it is involved in the regulation of the blood-brain barrier and the maintenance of the integrity of neuronal cells.

Drugs that interact with CLDN8

Several drugs have been developed to target CLDN8 and have been shown to have various therapeutic effects. These drugs include:

1. Statins: Statins are a class of drugs that is used to treat high cholesterol. They work by inhibiting the production of low-density lipoprotein (LDL) cholesterol in the liver, which is a major risk factor for heart disease. Some studies have shown that statins can increase the expression of CLDN8 in endothelial cells, which may contribute to their potential cardiovascular benefits.
2. Valvular drugs: Valvular drugs are a class of drugs used to treat heart valve disease. They treat high cholesterol by inhibiting the liver's production of low-density lipoprotein (LDL) cholesterol. Some studies have shown that valvular drugs can increase the expression of CLDN8 in endothelial cells, which may be one of the reasons for their potential therapeutic effect in heart valve disease.
3. Angiotensin-converting enzyme inhibitors (ACEIs): ACEIs are a class of drugs used to treat high blood pressure. They lower blood pressure by inhibiting angiotensin-converting enzyme. Some studies have shown that ACEIs may enhance their antihypertensive effects by increasing the expression of CLDN8 in endothelial cells.
4. Anti-neuronal drugs: Anti-neuronal drugs are a class of drugs used to treat neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. They treat these diseases by inhibiting the death or damage of neurons. Some studies have shown that anti-neuronal drugs may promote the development of neurodegenerative diseases by increasing the expression of CLDN8 in endothelial cells.

Conclusion

CLDN8 is a very important protein that plays an important role in cell adhesion, signal transduction, and the occurrence of neurodegenerative diseases. Due to its importance and complexity, CLDN8 has emerged as an important drug target. Future research will continue to explore the role of CLDN8 in treating various diseases and develop more effective drugs to target CLDN8.

Protein Name: Claudin 8

Functions: Tight-junction protein required for paracellular chloride transport in the kidney. Mediates recruitment of CLDN4 to tight junction in the kidney. Claudins play a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity

The "CLDN8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets